Antibody-drug conjugates (ADCs) represent a revolutionary advancement in the struggle against cancer. ADCs integrate the precision of antibodies with the destructive capability of cytotoxic drugs. By transporting these potent agents directly to tumor sites, ADCs enhance treatment efficacy while limiting harm to healthy organs. This focused approach